Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Combined With Pola-R-CHP in Untreated Non-GCB DLBCL
NCT07078500Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started May 2025; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07078500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07078500.